Co-Development Reports Sample Clauses

Co-Development Reports. Within forty-five (45) days after the end of each calendar quarter, Regeneron and Aventis shall each provide to the other Party a written report (in electronic form) summarizing the material activities undertaken by such Party during such quarter in connection with each Co-Development Plan, together with a statement of Development Costs incurred by such Party during such quarter.
Sample 1Sample 2
AutoNDA by SimpleDocs
Co-Development Reports. Within thirty (30) days after the end of each quarter, Regeneron and Novartis shall each provide to the other Party and to the JOC a written report (in electronic form) summarizing in reasonable detail the material activities undertaken by such Party during such quarter in connection with each Consolidated Co-Development Plan, together with a detailed project-level statement of Development Costs incurred by such Party during such quarter. 5.9 Loan Facilities for Trap-1 Product Development Costs. (a)
Sample 1
Co-Development Reports. At each JDC meeting, (a) Stoke shall provide the JDC a summary of the progress and results of Development activities for any SYNGAP1 Co-Co Product for which Stoke is the Lead Development Party or Lead Regulatory Party or otherwise responsible for, and (b) Acadia shall provide the JDC a summary of the progress and results of Development activities for any SYNGAP1 Co-Co Product for which Acadia is the Lead Development Party or Lead Regulatory Party or otherwise responsible for. Without limiting the foregoing, Acadia and Stoke shall each provide the JDC with a written report summarizing the Development activities for the SYNGAP1 Co-Co Products conducted by or on behalf of each Party since the last JDC meeting, including, as applicable (i) patient enrollment and the ongoing status of all Clinical Trials, in each case, under any SYNGAP1 Co-Development Plan, (ii) the status of each pending and proposed Regulatory Material submission and Regulatory Approval for each SYNGAP1 Co-Co Product for the Territory, and (iii) the conduct of material Medical Affairs activities (e.g., attendance at industry conferences), in each case to the extent not already provided.
Sample 1

Related to Co-Development Reports

  • Development Reports Beginning six months after Effective Date and ending on the date of first commercial sale of a Licensed Product in the United States, LICENSEE shall report to Cornell progress covering LICENSEE's (and Affiliate's and Sublicensee's) activities and efforts in the development of rights granted to LICENSEE under this Agreement for the preceding six months. The report shall include, but not be limited to, activities and efforts to develop and test all Licensed Products and obtain governmental approvals necessary for marketing the same. Such semi-annual reports shall be due within sixty days (60) of the reporting period and shall use the form as provided herein as Appendix C.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Research Reports Distributor acknowledges that Dealer may prepare research reports relating to the Fund that are not to be used for marketing purposes (“Research Reports”). Distributor hereby authorizes Dealer to use the name of the Fund, Distributor and BREDS in Research Reports.

  • Clinical Development Licensee will have sole responsibility for and sole decision making over the clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial.

  • Development Records Each Party shall maintain complete, current and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner [*]. Each Party shall document all non-clinical studies and clinical trials in formal written study reports according to applicable Laws and national and international guidelines (e.g., ICH, GCP, GLP, and GMP). Each Party shall have the right to review and copy such records maintained by the other Party at reasonable times and to obtain access to the original [*].

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Joint Development If joint development is involved, the Recipient agrees to follow the latest edition of FTA Circular 7050.1, “Federal Transit Administration Guidance on Joint Development.”

  • Progress Reports The Recipient shall submit to the OPWC, at the OPWC's request, summary reports detailing the progress of the Project pursuant to this Agreement and any additional reports containing such information as the OPWC may reasonably require.

  • Initial Development Plan Not later than the Effective Date, Licensee shall have provided Merck with an initial Development plan for the Licensed Product in the Field in the Territory, which shall be incorporated as part of this Agreement as Attachment 3.02(a) (as may be amended in accordance with this Agreement, the “Development Plan”). **CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  • Management Reports Promptly upon receipt thereof, copies of all detailed financial and management reports submitted to the Company by independent auditors in connection with each annual or interim audit made by such auditors of the books of the Company.

Time is Money Join Law Insider Premium to draft better contracts faster.